INOVIO to Participate in Upcoming Scientific Conferences
INOVIO (INO) will participate in scientific conferences covering hypophosphatasia and hemophilia in New York and Montreal in November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
INOVIO (INO) will participate in scientific conferences covering hypophosphatasia and hemophilia in New York and Montreal in November.
The company will present on rare disease protein replacement therapeutics at the Soft Bones meeting on November 8 and on INO-D001 for Hemophilia A at the World Federation of Hemophilia workshop on November 12. Abstracts and presentations will be added to its events page if available.
Details
Market Reaction – INO
On Nov 2, the day this news came out, the latest delayed price for INO is 1.61% below the previous close. Our momentum scanner has recorded 63 alerts for this stock so far that day. The latest delayed price is $1.86. Relative volume is exceptionally heavy at 71.5x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Soft Bones Third International Scientific Meeting on Hypophosphatasia (
Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine
Date: Sunday, November 8
World Federation of Hemophilia - New Technology & Gene Therapy (NTGT) Workshop (
Presentation: INO-D001 for Hemophilia A
Date: Thursday, November 12
Abstracts and presentations will be added to our events page if available.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302926885.html
SOURCE INOVIO Pharmaceuticals, Inc.